Medical Disclaimer
This article is for informational and educational purposes only and does not constitute medical advice. Research peptides discussed are not FDA-approved for human use. Always consult a licensed healthcare professional. See our full disclaimer.
Quick Answer: Survodutide is an investigational weekly subcutaneous peptide that activates both the glucagon receptor and the GLP-1 receptor. The dual mechanism produces greater weight loss than pure GLP-1 agonists while also driving hepatic fat clearance — making it particularly promising for both obesity and metabolic dysfunction-associated steatohepatitis (MASH). In Phase 2 trials survodutide produced ~19% weight loss at 46 weeks; Phase 3 SYNCHRONIZE data are maturing in 2026. The glucagon component accelerates energy expenditure and liver fat mobilization, while the GLP-1 component suppresses appetite. Survodutide is not yet FDA-approved but is progressing through late-stage development as part of the post-semaglutide generation of metabolic peptides.
What Is Survodutide?
Survodutide (BI 456906) is an investigational weekly peptide drug co-developed by Boehringer Ingelheim and Zealand Pharma. It is a dual glucagon receptor (GCG-R) and GLP-1 receptor (GLP-1R) agonist designed to produce substantial weight loss and liver fat reduction through complementary mechanisms.
Unlike tirzepatide (GIP + GLP-1) or retatrutide (GIP + GLP-1 + glucagon), survodutide focuses specifically on glucagon and GLP-1 — a combination that emphasizes energy expenditure, hepatic metabolism, and satiety.
Mechanism of Action
Glucagon Receptor Activation
Endogenous glucagon is known for raising blood sugar, but its physiologic role extends to energy expenditure, hepatic fat oxidation, and satiety. At therapeutic doses in the dual-agonist context, glucagon-receptor activation increases resting metabolic rate, drives hepatic fat clearance, and augments GLP-1-driven satiety.
GLP-1 Receptor Activation
GLP-1 agonism reduces appetite centrally, slows gastric emptying, and improves glucose control. Combined with glucagon activation, the net effect is enhanced weight loss with protection against hyperglycemia that pure glucagon activation would otherwise cause.
Net Effect
The dual activation profile produces more significant weight loss than GLP-1 alone while driving particularly strong reductions in liver fat — making survodutide especially relevant for MASH/NASH treatment.
Clinical Trial Data
Obesity Trials
Phase 2 data: survodutide produced approximately 19% weight loss at 46 weeks at the highest studied dose (4.8 mg weekly), versus ~2% for placebo. Adjusted for placebo, this is a highly competitive effect size.
Phase 3 SYNCHRONIZE trials are ongoing; topline data expected in 2026.
MASH/NASH Trials
Survodutide showed particularly strong effects on hepatic steatosis, with measurable reductions in liver fat fraction and improvements in MASH histology. Phase 2 MASH data demonstrated MASH resolution in ~83% of patients at 48 weeks at higher doses — one of the highest rates reported for any investigational MASH therapy. Phase 3 MASH trials are enrolling.
MASH is an underserved indication with ~20–30M affected patients in the US alone. A therapy effective for both obesity and MASH would be commercially and clinically transformative.
Dosing Framework
Based on Phase 2 and ongoing Phase 3 protocols, the typical dosing scheme appears to be:
| Week | Dose (mg weekly SC) |
|---|---|
| 1–4 | 0.3 |
| 5–8 | 0.6 |
| 9–12 | 1.2 |
| 13–16 | 2.4 |
| 17+ | 3.6–4.8 (maintenance, per response) |
As with other dual agonists, slow titration minimizes GI adverse effects and allows glucagon-related metabolic adjustments.
Side Effects and Safety
Side-effect profile reflects both GLP-1 and glucagon activation:
- GLP-1 effects: Nausea, vomiting, diarrhea, constipation, gallbladder issues
- Glucagon effects: Mild blood glucose elevation (mitigated by GLP-1 component); potential cardiovascular considerations at higher doses
- Injection site reactions: Minimal
- Fatigue and headache: Early adaptation phase
Glucagon-related cardiovascular monitoring (blood pressure, heart rate) is important, especially at higher doses. Diabetic patients may need closer glucose monitoring.
Survodutide vs Other Multi-Agonists
| Compound | Mechanism | Weight Loss | MASH Activity |
|---|---|---|---|
| Semaglutide | GLP-1 | ~15% | Modest |
| Tirzepatide | GIP + GLP-1 | ~22.5% | Moderate |
| Cagrisema | Amylin + GLP-1 | ~20% | Modest |
| Survodutide | Glucagon + GLP-1 | ~19% | Strong |
| Retatrutide | GIP + GLP-1 + Glucagon | ~24% | Strong (inferred) |
Survodutide's niche is MASH-focused obesity therapy. For patients with obesity + significant liver disease, survodutide may become the preferred choice.
Survodutide for Liver Disease
MASH (metabolic dysfunction-associated steatohepatitis) represents a large unmet medical need. Survodutide's MASH trial results are particularly impressive, with both reduced liver fat and histological MASH resolution. The glucagon component drives hepatic fat oxidation in ways that pure GLP-1 agonists cannot match.
If approved for MASH, survodutide could redefine treatment of this condition alongside resmetirom and other emerging MASH therapies.
Expected Access and Pricing
FDA approval is expected 2027–2028 pending Phase 3 completion. Pricing is likely to match or exceed semaglutide given the novel mechanism and dual indications (obesity + MASH). Insurance coverage for MASH specifically may be more generous than for obesity alone, potentially driving patient preference.
Bottom Line
Survodutide is one of the more promising next-generation peptides for patients with both obesity and liver disease. Its dual glucagon/GLP-1 mechanism produces competitive weight loss plus particularly strong hepatic effects. While it may not claim the weight-loss crown (retatrutide appears to), its MASH-focused profile offers clinical value that pure GLP-1s and GIP/GLP-1 dual agonists don't match. Expect survodutide to become a meaningful option for obesity + MASH and for patients seeking alternatives to GIP-containing compounds.
Recommended Research Vendors
For researchers sourcing compounds discussed in this article, the following vendors maintain third-party purity testing, transparent sourcing, and established reputations in the research peptide community. WolveStack earns a small commission on referred purchases, which funds our research and writing work — this does not affect our editorial evaluation of each vendor.
🧪 Ascension Research
Third-party tested research peptides. Transparent COAs, reliable sourcing, and fast shipping make Ascension a top choice for researchers.
Visit Ascension →🧬 Particle Peptides
Pharma-grade purity with full HPLC/MS certificates for every batch. Particle is known for clinical-grade quality and precision research protocols.
Visit Particle →💎 Limitless Life
Popular for novel and hard-to-source research compounds. Limitless offers a broad catalog of frontier peptides backed by third-party testing.
Visit Limitless →Frequently Asked Questions
No. Survodutide is currently in Phase 3 clinical trials. FDA and EMA approval is expected 2027–2028 at earliest. It is not commercially available in 2026.
The glucagon component does raise blood sugar modestly, but this is counterbalanced by the GLP-1 activation. Net effect is generally neutral or mildly favorable for glucose control. Patients with diabetes may need closer monitoring, particularly at higher doses.
Tirzepatide combines GIP and GLP-1; survodutide combines glucagon and GLP-1. Both are dual agonists but target different pathways. Tirzepatide produces slightly greater weight loss; survodutide has stronger effects on liver fat and MASH. Side-effect profiles differ accordingly.
Phase 2 trials showed strong MASH resolution rates (~83% at higher doses). If Phase 3 confirms these results, survodutide could become an FDA-approved therapy for both MASH and obesity, addressing a major unmet medical need.
Approximately 19% body weight loss at 46 weeks at highest dose in Phase 2 trials. Phase 3 results are still maturing but expected in similar range. This places survodutide between semaglutide (~15%) and tirzepatide (~22.5%).
Both are in development; safety data continue to accumulate. Retatrutide's triple-agonist action may produce more weight loss but potentially more significant side effects. Survodutide's dual mechanism may offer a gentler profile. Direct head-to-head data are not yet available.
Yes, through its GLP-1 component. Expect HbA1c reductions comparable to other GLP-1 class drugs. The glucagon component is balanced so as not to worsen glucose control despite glucagon's natural glucose-raising role.
Compounded versions are unlikely before approval. Survodutide is not on FDA shortage lists (which enable compounding for semaglutide/tirzepatide). Research-grade survodutide may be available but is not suitable for patient use.
You Might Also Like
About the Author
The WolveStack research team compiles peer-reviewed scientific literature, clinical trial data, and accumulated biohacking community experience to deliver evidence-first peptide education. Our guides reflect the current state of research and common practices in the researcher community, with emphasis on critical evaluation and transparent discussion of what is and isn't known.